The stock of scPharmaceuticals Inc (SCPH) has seen a -15.97% decrease in the past week, with a -14.17% drop in the past month, and a 1.14% flourish in the past quarter. The volatility ratio for the week is 6.32%, and the volatility levels for the past 30 days are at 5.30% for SCPH. The simple moving average for the past 20 days is -13.72% for SCPH’s stock, with a -12.03% simple moving average for the past 200 days.
Is It Worth Investing in scPharmaceuticals Inc (NASDAQ: SCPH) Right Now?
The 36-month beta value for SCPH is also noteworthy at 0.13. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SCPH is 35.23M, and at present, short sellers hold a 12.08% of that float. The average trading volume of SCPH on September 27, 2024 was 268.61K shares.
SCPH) stock’s latest price update
The stock price of scPharmaceuticals Inc (NASDAQ: SCPH) has dropped by -4.74 compared to previous close of 4.64. Despite this, the company has seen a fall of -15.97% in its stock price over the last five trading days. zacks.com reported 2024-08-16 that The mean of analysts’ price targets for scPharmaceuticals (SCPH) points to a 291.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Analysts’ Opinion of SCPH
Many brokerage firms have already submitted their reports for SCPH stocks, with Craig Hallum repeating the rating for SCPH by listing it as a “Buy.” The predicted price for SCPH in the upcoming period, according to Craig Hallum is $20 based on the research report published on September 07, 2023 of the previous year 2023.
Cowen, on the other hand, stated in their research note that they expect to see SCPH reach a price target of $25. The rating they have provided for SCPH stocks is “Outperform” according to the report published on December 01st, 2022.
Jefferies gave a rating of “Buy” to SCPH, setting the target price at $14 in the report published on October 21st of the previous year.
SCPH Trading at -10.59% from the 50-Day Moving Average
After a stumble in the market that brought SCPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.33% of loss for the given period.
Volatility was left at 5.30%, however, over the last 30 days, the volatility rate increased by 6.32%, as shares sank -10.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.49% lower at present.
During the last 5 trading sessions, SCPH fell by -15.97%, which changed the moving average for the period of 200-days by -23.92% in comparison to the 20-day moving average, which settled at $5.10. In addition, scPharmaceuticals Inc saw -29.51% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SCPH starting from ORBIMED ADVISORS LLC, who purchase 500,000 shares at the price of $4.00 back on Aug 13 ’24. After this action, ORBIMED ADVISORS LLC now owns 5,806,670 shares of scPharmaceuticals Inc, valued at $2,000,000 using the latest closing price.
Stock Fundamentals for SCPH
Current profitability levels for the company are sitting at:
- -2.51 for the present operating margin
- 0.71 for the gross margin
The net margin for scPharmaceuticals Inc stands at -2.52. The total capital return value is set at -1.15. Equity return is now at value -166.89, with -67.52 for asset returns.
Based on scPharmaceuticals Inc (SCPH), the company’s capital structure generated 0.81 points at debt to capital in total, while cash flow to debt ratio is standing at -1.66. The debt to equity ratio resting at 4.34. The interest coverage ratio of the stock is -14.15.
Currently, EBITDA for the company is -54.77 million with net debt to EBITDA at -0.05. When we switch over and look at the enterprise to sales, we see a ratio of 9.31. The receivables turnover for the company is 3.93for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.84.
Conclusion
In summary, scPharmaceuticals Inc (SCPH) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
